Development and Validation of Flow Cytometry-Based Method to Quantify CD34/CD45+ Cells as a Release Criterion of Clinical-Grade Products for a Phase III Clinical Trial.

Published 04/01/2026

Research record: Development and Validation of Flow Cytometry-Based Method to Quantify CD34/CD45+ Cells as a Release Criterion of Clinical-Grade Products for a Phase III Clinical Trial.

Published in Cytometry A; first publication date 2026-04-01. PMID 42071167.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Read the original publication on PubMed

Talk to a Specialist Browse all insights

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-04-01

Updated

2026-10-20

Disclaimer

professional use

References